Download to read offline
Uploaded byVigilare Biopharma
R21 Malaria Vaccine
The R21 malaria vaccine demonstrates a 75% reduction in symptomatic malaria cases during the first year after a 3-dose regimen and maintains its efficacy with a fourth dose given a year later. It shows good efficacy across various transmission settings and is considered cost-effective at $2-$4 per dose. The vaccine is expected to be available in mid-2024, with plans for implementation in at least 28 African countries.
R21 Malaria Vaccine
- 1. R21/Matrix-M A New Hopefor Maleria Prevention NEW VACCINE UPDATE Vigilarebp.com
- 2. Key features of the R21malaria vaccine Vigilarebp.com 2/9 R21
- 3. IN AREAS WITHHIGHLY SEASONAL MALARIA TRANSMISSION, THE R21 VACCINE WAS SHOWN TO REDUCE SYMPTOMATIC CASES OF MALARIA BY 75% DURING THE 12 MONTHS FOLLOWING A 3-DOSE SERIES. A FOURTH DOSE GIVEN A YEAR AFTER THE THIRD MAINTAINED EFFICACY. THIS HIGH EFFICACY IS SIMILAR TO THE EFFICACY DEMONSTRATED WHEN RTS,S IS GIVEN SEASONALLY. High efficacy when given just before the high transmission season Vigilarebp.com 3/9
- 4. Good efficacy when givenin an age-based schedule THE VACCINE SHOWED GOOD EFFICACY (66%) DURING THE 12 MONTHS FOLLOWING THE FIRST 3 DOSES. A FOURTH DOSE A YEAR AFTER THE THIRD MAINTAINED EFFICACY. Vigilarebp.com 4/9
- 5. High Impact MATHEMATICAL MODELLING ESTIMATESINDICATE THE PUBLIC HEALTH IMPACT OF THE R21 VACCINE IS EXPECTED TO BE HIGH IN A WIDE RANGE OF MALARIA TRANSMISSION SETTINGS, INCLUDING LOW TRANSMISSION SETTINGS. Vigilarebp.com 5/9
- 6. Cost Effectiveness AT PRICESOF US$ 2 – US$ 4 PER DOSE, THE COST-EFFECTIVENESS OF THE R21 VACCINE WOULD BE COMPARABLE WITH OTHER RECOMMENDED MALARIA INTERVENTIONS AND OTHER CHILDHOOD VACCINES. Vigilarebp.com 6/9
- 7. Safety THE R21 VACCINEWAS SHOWN TO BE SAFE IN CLINICAL TRIALS. AS WITH OTHER NEW VACCINES, SAFETY MONITORING WILL CONTINUE. Vigilarebp.com 7/9
- 8. The R21 malaria vaccineis expected to become available to countries mid-2024. AT LEAST 28 COUNTRIES IN AFRICA PLAN TO INTRODUCE A WHO- RECOMMENDED MALARIA VACCINE AS PART OF THEIR NATIONAL IMMUNIZATION PROGRAMMES. GAVI, THE VACCINE ALLIANCE HAS APPROVED PROVIDING TECHNICAL AND FINANCIAL SUPPORT TO ROLL OUT MALARIA VACCINES TO 18 COUNTRIES. THE RTS,S VACCINE WILL BE ROLLED OUT IN SOME AFRICAN COUNTRIES IN EARLY 2024. Vigilarebp.com 8/9
- 9. Vigilarebp.com Follow us Biopharma PvtLtd For important updates and pharmacovigilance Tips